Huons Secures All-A Grade in South Korea’s ESG Ratings for Second Straight Year

News | 2025-11-19 18:47:57
[mediK / HEALTH IN NEWS] South Korean pharmaceutical company Huons Co. said Wednesday that it has earned a comprehensive A rating in the country’s closely watched environmental, social and governance evaluation for the second consecutive year, with top marks across all three categories.

In the 2024 assessment conducted by the Korea Institute of Corporate Governance and Sustainability (KCGS), formerly known as the Korea Corporate Governance Service, Huons received an A in environmental responsibility, an A in social responsibility and an A in governance—the latter representing an upgrade from the B+ it received a year earlier. The company maintained its A grades in the environment and social categories.

The results carry particular weight because this year's evaluation was the first to fully include operations at Huons’s newly opened Jecheon Plant No. 2, which began production in 2024.

Corporate logo of Huons. (Courtesy of Huons)
Corporate logo of Huons. (Courtesy of Huons)


In the environmental category, Huons was recognized for systematizing its response to climate change and strengthening environmental performance management. On the social front, the company conducted human-rights impact assessments and implemented enhanced occupational health and safety policies. In governance, it improved transparency by expanding disclosure of board and shareholder-meeting information.
Looking ahead, Huons said it plans to extend its sustainability framework across the broader Huons Group, intensify greenhouse-gas reduction efforts and tighten supply-chain ESG oversight.

Song Soo-young, chief executive of Huons, said the back-to-back comprehensive A ratings reflect the company’s commitment to embedding sustainable practices throughout its operations. “As a pharmaceutical company, we will continue to fulfill our responsibilities to society and the environment,” he added.

The KCGS evaluation is one of South Korea’s benchmark ESG assessments and is widely referenced by domestic institutional investors.

Lim Hye Jung medi·K TEAM press@themedik.kr
Copyright © 2020 mediK. All rights reserved.